Login to Your Account



FDA Hears Complexities of Biosimilar Implementation

By Donna Young


Wednesday, November 3, 2010
SILVER SPRING, Md. – The FDA Tuesday began facing some of the complexities it must deal with in developing regulations and guidelines for makers of follow-on biologics, or biosimilars, as various stakeholders in eight-minute presentations at a public meeting spelled out some of their ideas and concerns, such as whether biosimilars should carry the same generic-type name, known officially as the international nonproprietary name (INN), as the innovator drugs on which they are based. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription